R. Dirk Allison - Nov 25, 2024 Form 4/A - Amendment Insider Report for Addus HomeCare Corp (ADUS)

Role
CEO and Chairman, Director
Signature
/s/ Brian Poff, Attorney-in-Fact for R. Dirk Allison
Stock symbol
ADUS
Transactions as of
Nov 25, 2024
Transactions value $
-$1,293,181
Form type
4/A - Amendment
Date filed
11/27/2024, 05:35 PM
Date Of Original Report
Nov 26, 2024
Previous filing
Feb 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADUS Common Stock Options Exercise $246K +12.5K +15.74% $19.71 91.9K Nov 25, 2024 Direct F1
transaction ADUS Common Stock Sale -$425K -3.47K -3.77% $122.58 88.4K Nov 25, 2024 Direct F2, F3
transaction ADUS Common Stock Sale -$1.05M -8.52K -9.63% $123.31 79.9K Nov 25, 2024 Direct F2, F4
transaction ADUS Common Stock Sale -$31.4K -253 -0.32% $124.19 79.7K Nov 25, 2024 Direct F2, F5
transaction ADUS Common Stock Sale -$32.9K -263 -0.33% $125.17 79.4K Nov 25, 2024 Direct F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADUS Employee Stock Option (right to buy) Options Exercise $0 -12.5K -14.29% $0.00 75K Nov 25, 2024 Common Stock 12.5K $19.71 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Form 4 filed on 11/26/2024 erroneously reported 75,000 options exercised in column 4 of Table I and columns 5 and 7 of Table II. The purpose of this amendment is to correct those amounts and the related totals in column 5 of Table I.
F2 This transaction reflects the sale of shares made pursuant to a previously established 10b5-1 plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.92 to $123.91, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.95 to $124.22, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.93 to $125.25, inclusive.
F7 All options are fully vested.